Precision in cancer care increasingly relies on the integration of advanced imaging techniques to guide treatment and monitor outcomes. Imaging-Guided Therapy & Response Assessment enables clinicians to visualize tumors in real time, facilitating targeted interventions such as surgery, radiation therapy, and minimally invasive procedures. Techniques including CT, MRI, PET, and hybrid imaging modalities provide detailed anatomical, functional, and metabolic information, allowing for accurate tumor localization and treatment planning. By leveraging imaging data, healthcare teams can minimize collateral damage to healthy tissue, optimize therapeutic delivery, and enhance overall treatment efficacy. This approach is particularly crucial in complex or hard-to-reach tumors, where precision directly affects patient prognosis and long-term outcomes.
In addition, Imaging-Guided Therapy & Response Assessment supports dynamic evaluation of treatment response and early detection of disease progression. Functional and molecular imaging can reveal metabolic and microenvironmental changes before they are visible through traditional anatomical methods. Incorporating imaging biomarkers and standardized response criteria allows clinicians to adjust therapy in real time, refine risk stratification, and tailor treatment strategies to individual patient needs. By combining advanced imaging with multidisciplinary collaboration, imaging-guided therapy and response assessment strengthen precision oncology, enabling adaptive, personalized interventions that maximize therapeutic effectiveness while minimizing adverse effects and improving overall patient care.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation